Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
My post was Now under .02 suckerssssssss
I have SeeeennnnnnnnMUCHHHHHHHHHHHHHHHHHHHHHHHHH worse
explain please or i will report you suckerrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrr
Any reason for UVIH tank?
Street.com KILLED DVAX!
DVAX encore! I love it here especially after today. It looks like we are set up technically to take out $9 possibly tomorrow and i believe we could see $10 by Wednesday's close. As stated before, i find DVAX one of the most exciting biotech plays in some time. If things go according to plan, DVAX could become a behemoth.
Any morning dip we get tomorrow, i suggest buying the stock.
Good for daytrade. Intermediate and longer term i believe it will trade way above $10.
DVAX>>Next ACOR..Read...Buy of the year. I myself suffer from terrible Ragweed. I would be ALL OVER THIS DRUG!!
Pacific Growth analyst: at least $20 7-Oct-06 10:30 am
Conclusions and outlook
We believe that DVAX is making solid progress pushing Heplisav and
Tolamba through development and towards commercialization, and the recent
investment in Symphony Dynamo would potentially generate value in the early
pipeline as well. Upcoming catalysts in the next 6-9 months include data
release from the Phase III Heplisav study in older adults during Q4:06, and
one-year data from the Tolamba DARTT study and two-year data from the Tolamba
pediatric study during Q1:07. We expect these studies to be positive, which we
think may lead to partnership deals significant to the Company. We continue to
believe the technology value for Heplisav and Tolamba to be $7 and $13/share on
conservative assumptions, respectively. With approximately one year of cash on
the balance sheet, the Company commented that various financing options are
being sought, and we suspect a financing event could occur by YE:06. We believe
the short cash runway has likely created an overhang on the Stock. We reiterate
our Buy rating ahead of the upcoming catalysts and on what we feel is a
compelling valuation.
DVAX>>Next ACOR..Read...Buy of the year.
Pacific Growth analyst: at least $20 7-Oct-06 10:30 am
Conclusions and outlook
We believe that DVAX is making solid progress pushing Heplisav and
Tolamba through development and towards commercialization, and the recent
investment in Symphony Dynamo would potentially generate value in the early
pipeline as well. Upcoming catalysts in the next 6-9 months include data
release from the Phase III Heplisav study in older adults during Q4:06, and
one-year data from the Tolamba DARTT study and two-year data from the Tolamba
pediatric study during Q1:07. We expect these studies to be positive, which we
think may lead to partnership deals significant to the Company. We continue to
believe the technology value for Heplisav and Tolamba to be $7 and $13/share on
conservative assumptions, respectively. With approximately one year of cash on
the balance sheet, the Company commented that various financing options are
being sought, and we suspect a financing event could occur by YE:06. We believe
the short cash runway has likely created an overhang on the Stock. We reiterate
our Buy rating ahead of the upcoming catalysts and on what we feel is a
compelling valuation.
DVAX>>Next ACOR..Read...Buy of the year.
Pacific Growth analyst: at least $20 7-Oct-06 10:30 am
Conclusions and outlook
We believe that DVAX is making solid progress pushing Heplisav and
Tolamba through development and towards commercialization, and the recent
investment in Symphony Dynamo would potentially generate value in the early
pipeline as well. Upcoming catalysts in the next 6-9 months include data
release from the Phase III Heplisav study in older adults during Q4:06, and
one-year data from the Tolamba DARTT study and two-year data from the Tolamba
pediatric study during Q1:07. We expect these studies to be positive, which we
think may lead to partnership deals significant to the Company. We continue to
believe the technology value for Heplisav and Tolamba to be $7 and $13/share on
conservative assumptions, respectively. With approximately one year of cash on
the balance sheet, the Company commented that various financing options are
being sought, and we suspect a financing event could occur by YE:06. We believe
the short cash runway has likely created an overhang on the Stock. We reiterate
our Buy rating ahead of the upcoming catalysts and on what we feel is a
compelling valuation.
DVAX>>Next ACOR..Read...Buy of the year.
Pacific Growth analyst: at least $20 7-Oct-06 10:30 am
Conclusions and outlook
We believe that DVAX is making solid progress pushing Heplisav and
Tolamba through development and towards commercialization, and the recent
investment in Symphony Dynamo would potentially generate value in the early
pipeline as well. Upcoming catalysts in the next 6-9 months include data
release from the Phase III Heplisav study in older adults during Q4:06, and
one-year data from the Tolamba DARTT study and two-year data from the Tolamba
pediatric study during Q1:07. We expect these studies to be positive, which we
think may lead to partnership deals significant to the Company. We continue to
believe the technology value for Heplisav and Tolamba to be $7 and $13/share on
conservative assumptions, respectively. With approximately one year of cash on
the balance sheet, the Company commented that various financing options are
being sought, and we suspect a financing event could occur by YE:06. We believe
the short cash runway has likely created an overhang on the Stock. We reiterate
our Buy rating ahead of the upcoming catalysts and on what we feel is a
compelling valuation.
DVAX>>Next ACOR..Read...Buy of the year.
Pacific Growth analyst: at least $20 7-Oct-06 10:30 am
Conclusions and outlook
We believe that DVAX is making solid progress pushing Heplisav and
Tolamba through development and towards commercialization, and the recent
investment in Symphony Dynamo would potentially generate value in the early
pipeline as well. Upcoming catalysts in the next 6-9 months include data
release from the Phase III Heplisav study in older adults during Q4:06, and
one-year data from the Tolamba DARTT study and two-year data from the Tolamba
pediatric study during Q1:07. We expect these studies to be positive, which we
think may lead to partnership deals significant to the Company. We continue to
believe the technology value for Heplisav and Tolamba to be $7 and $13/share on
conservative assumptions, respectively. With approximately one year of cash on
the balance sheet, the Company commented that various financing options are
being sought, and we suspect a financing event could occur by YE:06. We believe
the short cash runway has likely created an overhang on the Stock. We reiterate
our Buy rating ahead of the upcoming catalysts and on what we feel is a
compelling valuation.
DVAX>>Next ACOR..Read...Buy of the year.
Pacific Growth analyst: at least $20 7-Oct-06 10:30 am
Conclusions and outlook
We believe that DVAX is making solid progress pushing Heplisav and
Tolamba through development and towards commercialization, and the recent
investment in Symphony Dynamo would potentially generate value in the early
pipeline as well. Upcoming catalysts in the next 6-9 months include data
release from the Phase III Heplisav study in older adults during Q4:06, and
one-year data from the Tolamba DARTT study and two-year data from the Tolamba
pediatric study during Q1:07. We expect these studies to be positive, which we
think may lead to partnership deals significant to the Company. We continue to
believe the technology value for Heplisav and Tolamba to be $7 and $13/share on
conservative assumptions, respectively. With approximately one year of cash on
the balance sheet, the Company commented that various financing options are
being sought, and we suspect a financing event could occur by YE:06. We believe
the short cash runway has likely created an overhang on the Stock. We reiterate
our Buy rating ahead of the upcoming catalysts and on what we feel is a
compelling valuation.
DELTE>>>DELETE>>>DELETE....Funny.
No it wont.
You guys still want to bash me as all of the shares you bought in the 3's and 4's are down HUGE right now?
Not angry at all, not one bit. Just trying to keep things level here. Open the case!
Stock was in the low .02's when symbol switched and went to the mid .05's almost immediately...now in the mid to high .02's. Explain away my friend....
Do you have an endless supply of money? You are always adding....I would like to be your banker.
Stock looks really weak. Headed for .02 or so.
UVIH...one of the best buys I have ever come across.
Love UVIH here. Florida Hurricane Insurer going to make a killing this year. Took on a lot of risk others didnt want and premiums are up almost 300%. Stock under 2 bucks and offering a .05 dividend in a few weeks. Might make close to a buck this year in earnings.
I was right wasnt I? So why would you tell me to STFU???
I thought they had all sold already? And wasnt that going to cause some mysterious buying frenzy? And wasnt the great PR going to send this to .50? On and on and on....Its done, stick a fork in it My King.
Where did you go my King? ;)
BAMMMMM...Theres your .02's! Get ready for .01's by end of the week. :)
Its called pumping my position. :)
Get ready for the .02's people!!
You're right. Next week they are opening a hot dog stand if front of the shop. A free hot dog for anyone buying a diamond! LOL
Wait, wait, wait...YOU"RE the NEGGER who is also in IVFH and IM the one who is clueless?? HAHAHAHAHAHAHAHA....I tried warning you on that POS too and you didnt listen, maybe you will on this one. IVFH>>>LOLOLOLOLOLOL....Get a clue!
I honestly believe you are insane!
"Blow the market wide open" LOL. This is just one of THOUSANDS of diamond shops..Gimme a break.
This sounds like a Mom and Pop diamond store that has already closed shop once...Hmmmm, not what I was expecting.
"Global Diamond Exchange originally opened their office on 2 West 46th Street in the heart of the 'New York's Diamond District'. After several years of operation at their New York office the company decided to shut down the operation due to low pricing and soft demand in North America. The company concentrated its efforts on exporting cut diamonds from the Russia Federation and European locations. The new company has reopened its sales offices in the original building ready to take on the increased demand for fine quality diamonds."
Uhhh...so what this is all about is a wholesale diamond store? Arent those a dime a dozen, especially in NYC? Funny...
What???
Why do you keep saying this over and over? Do you think I am just making this stuff up? Why? I know of at least 5 Ameritrade accounts, both Apex and Izone that have FROZEN any WWCD and GBDX shares..At the moment I have a 1 million dollar margin call because of this BS! Between the 5 of us we have over 3 million GBDX shares that I GUARANTEE you we will be selling as soon as we can. Now get that through your head and stop spouting lies!
Would you get it through your head once and for all....NO AMERITRADE accounts have been able to sell ANYTHING!
Thats not true. Most trade through AT and NO ONE had any of their shares today.
Did you know about this? Sounds fishy.
http://biz.yahoo.com/iw/060322/0114228.html
That is unreal. I had no idea.
Ameritrade isnt allowing me to trade any of my WWCD period, either online or brokers.
I had no idea WWCD has done this before.
Wait, WWCD has done this before? Oh shat.
I would like to know who they are. I dont know anyone able to sell and we have millions of shares. When those hit the street, and dont kid yourself, you know they will, this could take a big hit. Just wish Ameritrade didnt suck so bad and I could have sold some today. Being realistic.